News Center
Expert Consensus: Recommended Lijun Antiviral Granules for Mild and Moderate COVID-19 Infections
Release time:
2022-03-15
Recently, undertaken by the Respiratory Disease Drug Research Professional Committee of the China Traditional Chinese Medicine Association, and referring to the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Seventh Edition)" and "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Eighth Edition)" issued by the National Health Commission and the State Administration of Traditional Chinese Medicine, a consensus on the prevention and treatment of novel coronavirus pneumonia using traditional Chinese medicine has been formulated. The consensus has been officially published online in the "Chinese Journal of Integrative Medicine". The antiviral granules from Livzon Pharmaceutical Group have been included in this consensus. The expert consensus points out that for mild patients (clinical manifestations mainly include fever, sore throat, and fatigue), as well as ordinary patients (clinical manifestations mainly include fever, body aches, cough, sore throat, and shortness of breath), the use of antiviral granules is recommended.
Antiviral granules (sugar-free approval number: National Medicine Standard Z20010127; sugar-containing approval number: National Medicine Standard Z20070007) area proprietary traditional Chinese medicine compound developed by Sichuan Guangda Pharmaceutical Co., Ltd., a subsidiary of Livzon Pharmaceutical Group, based on classic formulas for the treatment of upper respiratory tract infections and influenza,Class B products for clearing heat and detoxifying in the 2019 National Medical Insurance Directory.,NationalTraditional Chinese Medicine Protected Variety (Level II), "National Key New Product","Sichuan Province Famous and Excellent New Product","Chengdu Famous and Excellent Product"Function and Indications:Clears heat and eliminates dampness, cools the blood and detoxifies. Used for cold with wind-heat, febrile diseases, lung heat syndrome, symptoms include fever, headache, cough, dry throat, sore throat; upper respiratory tract infections and influenza, mumps with the above symptoms.Multiple studies have shown that it is effective in treating symptoms such as nasal congestion, runny nose, fever, sore throat, headache, fever, and body aches. Since its launch in 2001, the clinical efficacy has been confirmed, safety is good, and it has been widely recognized by medical staff and patients. It has won five provincial and ministerial-level science and technology awards, including the First Prize of Science and Technology from the Chinese Association of Traditional Chinese Medicine, the First Prize of Innovation in Industry-University-Research from China, the First Prize of Invention and Entrepreneurship Award from the China Invention Association, a gold medal at the 48th Geneva International Invention Exhibition, and four patent awards including the Excellent Patent Award in China, with 16 invention patents authorized.
As early as the beginning of the COVID-19 pandemic, Livzon Pharmaceutical Group, in collaboration with Sun Yat-sen University, also conducted research on the inhibitory effect of antiviral granules on inflammation caused by novel coronavirus infection. The study showed that antiviral granules have varying degrees of inhibitory effects on the upregulation of pro-inflammatory cytokines in the LPS stimulation model; in the novel coronavirus stimulation model, antiviral granules can partially inhibit the upregulation of pro-inflammatory cytokines.
In addition to being included in the above consensus,antiviral granules are also included in relevant guidelines, consensus, and plans such as:The Chinese Medical Association's "Guidelines for the Diagnosis and Treatment of Acute Upper Respiratory Tract Infections in Primary Care (Practical Edition - 2018)", the China Traditional Chinese Medicine Association's "Clinical Application Guidelines for Traditional Chinese Medicine in Treating Adult Influenza - 2020", the Chinese Association of Integrative Medicine and the Chinese Association of Traditional Chinese Medicine's "Expert Consensus on the Prevention and Treatment of Influenza in Children with Integrative Medicine - 2021", the China Traditional Chinese Medicine Association's "Expert Consensus on the Prevention and Treatment of Novel Coronavirus Pneumonia - 2022", Sichuan Province's "Technical Guidelines for the Prevention and Control of Novel Coronavirus Pneumonia with Traditional Chinese Medicine (Revised Edition)", Sichuan Province's "Preventive Recommendations for Traditional Chinese Medicine against COVID-19 - 2021", Guangdong Province's "Reference Drug Demand Directory for Medical Institutions in the Prevention and Control of COVID-19", Guangdong Province's "Traditional Chinese Medicine Treatment Plan for Novel Coronavirus Pneumonia (Trial Second Edition)", and Hebei Province's "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Fourth Edition)".
Related Information